At 38, an IVF shot on a kitchen table beats years of “trying”

When the author was 38, she and her husband didn’t start with months of “trying to conceive.” Instead, they moved straight to IVF, using fertility benefits both received through their employers. That mattered on an emotional and operational level, because the decision wasn’t driven by a diagnosis. It was driven by timing, risk, and the practical reality that the costs and logistics were easier to absorb.

The scene is almost aggressively specific: it was just the couple at their kitchen table, with IVF supplies laid out, and her standing half-naked with circles drawn on her belly for where to inject and where not to inject. Right as she was about to give herself the first shot, her husband let out a nervous laugh, she lost it, and she thought, “I can't do this. I'm throwing in the towel.” Even with that moment, she later explains the choice was proactive, not out of necessity. They chose IVF because they wanted it as their path, even though IVF is hard and expensive and emotionally intense.

So why does this story hit harder for decision-makers and boards than a typical “personal journey” piece? Because it exposes how fertility care is increasingly shaped by benefits design, not just medical need. In the author’s case, both she and her husband received fertility benefits through work, which reduced the financial burden and made the IVF option feel realistic earlier. The incentive structure is simple but powerful: when coverage reduces direct cost, couples can treat fertility treatment timelines like a business schedule instead of a waiting game.

Her core rationale is built around three reasons she chose IVF proactively at ages 38 to 39. First, delivering a healthy baby. She notes that at her age, the chances of miscarriage and genetic abnormalities increase, and that with IVF, PGT-A (preimplantation genetic testing for aneuploidy) can be used to screen embryos for chromosomal abnormalities before transferring to the uterus. The logic she describes is not vague hope; it is selection, with the goal of reducing risk by selecting a chromosomally normal embryo and lowering the chance of transferring an embryo with certain chromosomal conditions.

Second, time and flexibility. She and her husband delayed parenthood because they were late bloomers, both started new careers around 30, married five years later, and then a few years after that began trying for a baby. By the time she reached 38 going on 39, she says she chose IVF partly because aging affects egg quality. Her point is that with IVF, embryos are created and banked, so her age becomes “just a number” operationally, because the embryos can be available when the timing is right for them.

Third, money. She calls it a “true privilege” that both received fertility benefits through employers, making the financial burden of IVF not as heavy as it might have been. That detail matters beyond her personal spreadsheet: employer coverage can convert a medical decision that might otherwise be postponed into one that can be scheduled.

The author also gives the results from one round, which is the kind of concrete number that keeps stories from floating off into inspiration-meme territory. With one round of IVF, her body produced 34 eggs, resulting in 4 euploid embryos described as chromosomally normal. She also frames what happens if the first transfer is successful. If it works, she still has multiple embryos for future pregnancies, which could remove her age as a factor because the embryos have already been deemed chromosomally normal and viable for pregnancy. Importantly, she also says they do not know yet if the IVF journey will result in pregnancy.

For executives, the operational takeaway is that fertility decisions can behave like “benefit-enabled acceleration.” When coverage exists, couples may choose to act sooner even without infertility diagnoses or other red flags. The author explicitly says they have no infertility diagnoses and no genetic concerns, with only “high cholesterol, oops!” She describes IVF as emotionally and logistically difficult, but she insists she knows they made the right choice for their family, partly because IVF can “carefully select the best, most healthy embryos” and partly because it gives them time back.

Zoom out one layer: this is also about second-order impacts for organizations. When fertility benefits are offered, the utilization pattern can shift from reactive to proactive care. That can affect how benefits teams forecast spend, how insurers price coverage, and how employers think about talent retention. For many employees, family planning is not an abstract perk. It is a career risk calculation, and coverage can change whether people delay, pause, or pursue time-sensitive treatment.

There is also a governance and policy angle, even if the story is personal. PGT-A and embryo screening represent a medically consequential step, not just a version of IVF. The choices described here hinge on what treatments and testing are available within care pathways and what is covered under benefits. In other words, the decision is partly medical, partly financial, and partly administrative. For leaders watching workforce health trends, this story is a reminder that fertility benefits can drive real behavior change, not just optional supplementation.

And for peers making decisions in HR, finance, or boards: the stakes are straightforward. Time is described by the author as her “greatest, most expensive resource.” IVF is framed as a way to keep the timeline they want while they pursue pregnancy. If employer benefits can help couples avoid years of waiting, then benefits design is not just compensation. It becomes a lever that can shift when employees access care, how they plan their lives, and how organizations support long-term retention during some of the most emotionally and financially sensitive moments of adulthood.